New drug combo shows promise in Hard-to-Treat breast cancer
NCT ID NCT03959891
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This early-stage trial is testing whether adding an experimental drug called Ipatasertib to standard hormone therapy can help control metastatic hormone receptor positive breast cancer. The study involves 77 women whose cancer has spread and is no longer responding to usual treatments. Researchers are primarily checking for safety and side effects, while also tracking how long the cancer stays under control.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Ipatasertib (an AKT inhibitor) combined with hormone therapies like fulvestrant or letrozole
What this could lead to
If it works, this could point toward a new treatment option for metastatic hormone receptor positive breast cancer that has stopped responding to standard therapies.
What could go wrong
This is an early Phase 1 trial with only 77 participants, so it is primarily testing safety. The drug may not shrink tumors or improve survival, and side effects could be significant.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Massachusetts General Hospital Cancer Center
Boston, Massachusetts, 02115, United States